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Huntington’s disease (HD) is a progressive neurodegenerative disorder caused by a CAG repeat expansion
that encodes a polyglutamine tract in huntingtin (htt) protein. Dysregulation of brain iron homeostasis,
oxidative stress and neurodegeneration are consistent features of the HD phenotype. Therefore, en-
vironmental factors that exacerbate oxidative stress and iron dysregulation may potentiate HD. Iron
supplementation in the human population is common during infant and adult-life stages. In this study,
iron supplementation in neonatal HD mice resulted in deterioration of spontaneous motor running ac-
tivity, elevated levels of brain lactate and oxidized glutathione consistent with increased energetic
dysfunction and oxidative stress, and increased striatal and motor cortical neuronal atrophy, collectively
demonstrating potentiation of the disease phenotype. Oxidative stress, energetic, and anatomic markers
of degeneration were not affected in wild-type littermate iron-supplemented mice. Further, there was no
effect of elevated iron intake on disease outcomes in adult HD mice. We have demonstrated an inter-
action between the mutant huntingtin gene and iron supplementation in neonatal HD mice. Findings
indicate that elevated neonatal iron intake potentiates mouse HD and promotes oxidative stress and
energetic dysfunction in brain. Neonatal-infant dietary iron intake level may be an environmental
modiﬁer of human HD.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Huntington’s disease (HD) is a progressive autosomal dominant
neurodegenerative disorder caused by a CAG repeat expansion in
exon-1 of the huntingtin (htt) gene [1]. Disease onset is typically in
early adult life with a range from childhood to advanced age.
Degeneration occurs primarily in striatum and cerebral cortex [2].
Clinical signs of HD include involuntary movements dominated by
chorea, cognitive decline, executive dysfunction and weight loss.B.V. This is an open access article u
nary Sciences, University of
70, USA.
ren),
(J. Fox),
(L. Dodds),
gas),
ts@ﬂorey.edu.au (B. Roberts),
(J.H. Fox).CAG expansion size is the main determinant of HD age of onset [3]
and is an important modiﬁer of progression [4]. Non-huntingtin
genetic variability and environmental factors explain the remain-
ing variability in HD; however, speciﬁc genes and environmental
factors are poorly deﬁned [5].
Mutant htt protein mediates its neurodegeneration promoting
effects though pathways that include transcriptional dysregula-
tion, energetic dysfunction and oxidative stress [6–8]. Mutant htt
expression in HD brain results in elevated brain regional iron and
accumulation within neurons [9–11]. Iron is redox active and tight
homeostatic regulation is needed to prevent generation of reactive
oxygen species [12,13]. Dysregulation of iron homeostasis in HD
may therefore contribute to disease progression by promotion of
oxidative stress and interfere with diverse redox regulated path-
ways [14,15]. Iron homeostasis is mediated by the coordinated
activity of import, export and transport proteins whose levels are
regulated by whole body/brain iron status via iron-sensing pro-
teins [16]. Expression of some of these proteins is altered in mousender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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properties provide some protection in HD mice [10,17] supporting
a role of iron in HD onset and/or progression. Despite these ﬁnd-
ings, the extent to which deregulated iron metabolism contributes
to HD progression is unclear.
Iron, being an essential micronutrient, could inﬂuence HD
through dietary intake level. This possibility is relevant to human
HD because iron intake can vary widely in human infants through
the use of natural or iron-fortiﬁed milk and in adults via diet and
supplements. Neonatal mice supplemented with iron have de-
creased performance in neurobehavioral tests and increased iron
content in the basal ganglia as adults [18,19]. Further, neonatal
iron supplementation at a level equivalent to that found in iron-
fortiﬁed milk replacers results in potentiating effects on brain
aging and MPTP-induced Parkinsonism in mice [20]. Adult rats fed
a two-fold increase in dietary iron had signiﬁcantly increased iron
levels in the striatum and altered brain glutathione consistent
with oxidative stress [21]. Despite evidence that elevated iron in-
take can modify brain functions the relationship between iron
nutrition, peripheral and central iron status, and HD progression is
unknown.
The purpose of this study was to determine if elevated iron
intake promotes HD as measured by markers of oxidative and
energetic dysfunction, behavior and anatomic neurodegeneration.
Elevated iron nutrition was studied during the neonatal and adult-
life stages. The neonatal-life stage is a time of potential vulner-
ability to environmental effects on brain development that may
impact the brain in adulthood [22]. In the adult-life stage there
could be direct effects of dietary iron intake on neurodegeneration.
We used R6/2 HD mice as they recapitulate the human brain iron
phenotype and demonstrate rapid disease progression [10]. In-
creased iron intake during the neonatal period potentiated HD, as
determined by behavioral, oxidative and energetic stress markers
and quantitative neuropathology outcomes; effects of iron on
neonatal wild-type mice were negligible. Further, there was no
effect of adult iron supplementation on disease progression. The
ﬁndings demonstrate a novel genotype by environment interac-
tion in neonatal HD mice and suggest that iron intake level during
the neonatal period may be an environmental modiﬁer of human
HD.Materials and methods
Mouse maintenance
R6/2 HDmice were maintained by backcrossing HDmales with B6/
CBA F1 females. Tails were cut at approximately 3 weeks of age for
genotyping. Mice were weaned at 3.5 weeks. Animals were main-
tained in a 12-h alternating dark-light cycle. Access to food and water
was ad libitum. Each cage had a single mouse igloos (Bio-Serv) and
Sani Chip bedding (Harlan). CAG repeat sizes were monitored. Mice
used in the neonatal iron supplementation study had a CAG repeat
size in the range 180–185. Mice used in the adult iron supplementa-
tion study had a CAG repeat size in the range 150–160. The neonatal
study was conducted ﬁrst; due to expanding CAG repeat size in the
colony, the adult study was conducted with a newly established col-
ony. Based on previous studies in R6/2 mice, the target group sizes for
behavioral studies were 10–16 animals, and for biochemistry and
neuropathology studies 8–10 animals.
Experimental design and iron treatments
Female mice only were used in experiments as male mice were
kept for breeding. In the neonatal iron supplementation study,
mouse pups were administered 120 mg/g/day body weightcarbonyl iron or saline via oral gavage from post-natal days 10–17.
This dose has been used previously to model the feeding of a
human infant with an iron-fortiﬁed milk replacer [20]. Pups were
weighed daily prior to each gavage. Whole litters of mice were
randomly assigned treatments. Upon weaning pups were grouped
into cages of mice with the same genotype and treatment. In the
adult iron supplementation study female mice were assigned to
treatment groups at weaning. The standard food (LabDiets 5K67)
was changed to treatment casein-based diets at 5 weeks of age
and mice were maintained on these until sacriﬁced. Iron speciﬁed
diet contained 50 ppm (low/control), 150 ppm (medium) and
500 ppm (high) iron supplied as ferric citrate (Harlan). The
150 ppm concentration was chosen as this provides an equivalent
level of iron to standard commonly used cereal-based rodent
diets; 50 ppm is a low iron level but not sufﬁcient to result in iron
deﬁciency; and, 500 ppm was chosen to model a high-iron diet.
The levels of iron supplementation over basal iron intake were
chosen based on likely upper levels of iron supplementation in the
human population at different life stages. Based on absence of
premature mortality we found no evidence that iron dosing in
either the neonatal or the adult study resulted in toxicity.
Behavioral analyses
Spontaneous cage wheel running activity was used as a measure
of spontaneous activity as previously described [23]. Mice were
placed individually in cages with wireless running wheels (Med
Associates, Inc.) for 4 days. Data from days 2–4 was analyzed. Mice
were then returned to their home cages. Wheel analyses were
conducted at 5 and 10 weeks of age in the neonatal study, and at 4,
9, and 12 weeks of age in the adult study. These time points were
chosen in order to establish baseline behavioral performance and
to evaluate behavioral deterioration at various stages of disease
progression.
Accelerating rotarod was used to evaluate for motor endurance.
The rod accelerated from 5 to 25 rpm over 15 min. For each time
point there was an initial training day in which mice were placed
on the rota-rod for 5 min; mice that fell off were replaced on the
rotating rod. Data were collected on the subsequent 3 days. Mice
were placed on the rota-rod apparatus and were replaced on the
apparatus if a fall occurred within the ﬁrst 30 s of training. If a
mouse fell a second time within the ﬁrst 30 s the time was re-
corded and the trial ended. Any fall occurring after the initial 30 s
of the trial was recorded as the latency to fall. Mice were tested on
the rotarod at 5, 8, and 12 weeks of age in the neonatal study; in
the adult study mice were tested at 4.5, 8, 10, and 12 weeks of age.
Quantitative neuropathology and huntingtin aggregate analysis
Stereological analyses of neuronal cell body volumes was
completed using the Stereo Investigator software (MBF Bioscience,
Williston, VT) as described previously [24]. In brief, mice were
perfused for 3 min with heparinized 0.9% (w/v) saline then with
4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for
15 min. Brains were post-ﬁxed for 24 h then cryopreserved in 10%
glycerol, 2% DMSO and 0.1 M phosphate buffer for 5 days. Brains
were sectioned frontally at 40 mm and stored in phosphate buffer.
For Cavalieri estimation of striatal volume every 12th section was
mounted on a glass slide and stained using the thionin method.
Slides were letter-coded for blinding purposes. For nucleator es-
timation of striatal neuronal cell body volume a section at the level
of the anterior commissure only was analyzed. To quantify mutant
huntingtin aggregates we stained sections of striatum at the levels
of the anterior commissure. Sections were stained while ‘ﬂoating’
using a 1:1000 dilution of anti-huntingtin antibody (MAB5374,
Millipore) for 48 h; this was followed by a 24-h incubation in a
K.L. Berggren et al. / Redox Biology 4 (2015) 363–374 3651:500 dilution AF488-labeled secondary antibody (Invitrogen). We
used ﬂuorescent Nissl Neurotraces 640/660 (Invitrogen) to detect
neuron cell bodies. Z-stacks in dorso-medial and mid-lateral
striatum were captured using a Zeiss 710 confocal microscope and
60 oil objective then imported into stereo-investigator. Ag-
gregates were counted using the optical fractionator method with
a counting frame size of 2525 mm2 and grid size of 6767 mm2.
All neurons and aggregates falling within the counting frame were
counted separately. The proportion of neurons with aggregates for
the different HD groups was analyzed.
Western blot analysis
Mice were anesthetized then transcardially perfused with 0.9%
(w/v) saline containing 25 units/mL of heparin. Brains were re-
moved, dissected and frozen at 80 °C. Weighed brain regions
were homogenized in 12 volumes of a buffer comprising 20 mM
Tris (pH 7.5), 150 mM NaCl, 1% triton-X100 and a protease inhibitor
cocktail (Roche). Samples were then centrifuged for 12 min at
16,000g then supernatants aliquoted and stored at 80 °C.
Twenty micrograms of protein was separated by reducing SDS-
PAGE using 4–12% gradient gels then transferred to PVDF. Primary
antibody concentrations were: transferrin receptor (Invitrogen;
1:500), amyloid precursor protein (Millipore; 1:1000) and actin
(Sigma; 1:2000). HRP labeled secondary antibodies were used at
1:2000 dilution. Film was used for detection.
Oxidative and energetic markers
Glutathione (GSH) and oxidized glutathione (GSSG) were
measured as described previously [25]. Lactate was measured as
we have described previously [25,26].
Iron-analysis
Inductively-coupled-plasma mass spectroscopy (ICP-MS) was
used to quantify iron levels in brain and liver. Mice were perfused
with saline as described above. Dissected tissue was frozen then
weighed prior to ICP-MS analysis as described previously [10,27].
Size-exclusion chromatography ICP-MS (SEC-ICP-MS) was used to
quantify the amount of iron associated with the ferritin iron-sto-
rage protein fraction in brain. Frontal cortices were obtained as
described for Western blot analysis then homogenized in 20 mM
TRIS (pH 7.4), 100 mM NaCl and EDTA-free protease inhibitors
(Roche) at a ratio of 1:4 (w/v) with polypropylene pestle. The
protein concentration within the clariﬁed supernatant was de-
termined by measuring absorbance at 280 nm using a NanoDrop
spectrophotometer (Thermo, Fisher Scientiﬁc). Metalloproteomic
analysis was conducted as previously described [28,29]. In brief,
samples were normalized to the same protein concentration then
120 mg was injected on to a Bio-SEC 3 size-exclusion column
(4.6150 mm2, 3 mm 150 Å, Agilent). The samples were main-
tained at 4 °C prior to injection using a Peltier cooler autosampler
(Agilent 1200 series). The column was developed using 200 mM
NH4NO3 (trace metal basis, Sigma) (pH 7.8) with 10 mg/L of Cs and
Sb as internal standard at a ﬂow rate of 0.4 mL/min and 30 °C. The
efﬂuent from the column passed through a variable wavelength
detector (280 nm) before being directly plumbed to an Agilent
Technologies 7700 ICP-MS ﬁtted with a Mira Mist nebulizer
(Burgener research Inc., Ontario). The ICP-MS was operated using
helium as a collision gas (3.4 mL/min) to remove polyatomic in-
terferences. The ICP-MS was tuned daily using 1 mg/L Li, Co, Y, Ce
and Tl standard. The individual integration time for each element
was 0.1 s with a cycle time of 1.8 s. A standard curve for iron
(2000–60,000 pg) was developed using ferritin (GE healthcare)
dissolved in 0.1 M TRIS, pH 7.5. The concentration of iron in ferritinwas determined by standard bulk analysis techniques.
Serum iron and transferrin saturation
Blood was collected from heart following anesthesia but prior
to saline perfusions. Samples were centrifuged for 10 min at 5000g
then serum stored at 4 °C. Analyses were completed within
2 weeks. We used an iron/transferrin saturation kit that utilizes
the ferrozine method (Pointe Scientiﬁc, Inc.) and followed the
manufacturer’s instructions.
Statistical analyses
All data were analyzed using SAS software version 9.2 (Cary,
NC). The GLM procedure was used for one-way ANOVA (brain iron,
oxidized glutathione, lactate, huntingtin aggregates and cell body
volumes). The MIXED procedure was used for repeated-measures
analysis (rota-rod endurance and wheel running). Signiﬁcant dif-
ferences were determined by pre-planned pair-wise comparisons
only if there were signiﬁcant main effects or interactions in the
overall analysis. Results are summarized as mean7SEM (data had
normal distribution and variances were homogenous) except for
wheel running results which are provided as mean795% con-
ﬁdence; these data were right-skewed and was analyzed following
log transformation.Results
Neonatal iron supplementation alters behavioral outcomes
Impaired motor performance is a consistent outcome in R6/2
HD mice [10,30–32]. We measured spontaneous motor activity by
placing mice in cages with free access to a running wheel. There
were no differences in wheel-running behavior between iron and
saline-treated R6/2 and wild-type mice at 5 weeks of age con-
sistent with absence of a toxic effect of the iron dose. However, at
10 weeks of age, corresponding to early advanced disease, neo-
natal iron-supplemented HD mice had signiﬁcantly decreased
activity compared to saline-treated HD in both light (p¼0.0010)
and dark (p¼0.0175) phases (Fig. 1A and B). We also assessed
motor endurance on the rota-rod. There was a sharp signiﬁcant
decline in rota-rod endurance in HD mice at 8 and 12 weeks;
however, neonatal iron treatment did not affect Rota-rod perfor-
mance in R6/2 HD mice (Fig. 1C), suggesting a possible ﬂoor effect.
Survival analysis was not undertaken.
Neonatal iron treatment increases brain markers of oxidative stress
We analyzed three brain metabolite markers of redox and en-
ergetic state (GSH, GSSG, and lactate) in brain in 12-week-old mice
to investigate if behavioral effects of iron supplementation in HD
extend to involve established biochemical disease markers. Con-
sistent with our previous report [25], GSSG was not elevated in the
brains of control R6/2 HD compared to control wild-type mice at
12 weeks of age (Fig. 2A and B). However, neonatal iron supple-
mentation resulted in signiﬁcantly elevated GSSG in HD, but not
wild-type mice, in both striatum (p¼0.0006) and cortex
(p¼0.0002) (Fig. 2A and B). R6/2 HD mice had signiﬁcantly ele-
vated striatal and cortical GSH as we have reported previously
(data not shown) [25]. However, there was no effect of neonatal
iron supplementation on GSH in HD or wild-type mice; therefore
the increase of GSSG is not secondary to increased GSH. GSH: total
glutathione percent ratios in striatum and cortex were sig-
niﬁcantly decreased by neonatal iron supplementation in HD mice
(HD control¼94.5270.48, HD iron¼92.5270.48, p¼0.0006; and
Fig. 1. Neonatal iron supplementation decreases spontaneous wheel activity in R6/2 HD mice but has no effect on rota-rod activity. (A and B) Spontaneous wheel activity in
R6/2 and wild-type mice. Neonatal iron supplementation decreases spontaneous wheel activity in HD, but not wild-type mice, at 10 weeks of age in light (A) and dark
(B) periods. Mutant huntingtin expression (HD) decreases spontaneous wheel activity at 10 weeks in the dark but not light. Bars represent mean795% conﬁdence intervals.
(C) Rota-rod activity in R6/2 and wild-type mice. No effect of neonatal iron intake on rota-rod endurance. Graph bars: open¼wild-type; hatched¼HD; white¼no sup-
plementation; and gray¼ iron supplemented. n¼10 for both studies. Asterisks indicate levels of signiﬁcance: n o0.05, nn o0.01, nnn o0.001.
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spectively) but were not altered by iron treatment in wild-type
mice (WT control¼92.8370.48, WT iron¼97.77, p¼0.9145; and
WT control¼95.6070.48 WT iron¼95.6970.48, p¼0.8788, re-
spectively). We also measured brain lactate in the current study to
determine if changes in metabolic function are elicited by neonatal
iron supplementation. While there was increased lactate in HD
compared to wild-type mice, for reasons that are not clear, this
was not signiﬁcant in this study. Despite this, neonatal iron sup-
plementation increased striatal (p¼0.0036) and cortical
(p¼0.0293) lactate in HD, but not wild-type mice, when compared
to respective controls (Fig. 2C and D).
Early-life iron treatment decreases neuronal volume and huntingtin
aggregates in R6/2 mice
Neuronal cell body atrophy is a regular feature of mouse HD
[30,33]; this outcome is a valuable anatomic marker of HD pro-
gression in pre-clinical therapeutic studies [24]. To determine if
neonatal iron treatment exacerbated neuronal atrophy we quan-
tiﬁed, using unbiased stereology, cell body volumes in striatum
and layer V of primary motor cortex (Fig. 3). In striata (Fig. 3A andB) and motor cortex (C and D) cell body volumes were signiﬁcantly
decreased in HD controls compared to wild-type controls
(p¼0.0323 and 0.0279, respectively). Furthermore, iron supple-
mentation resulted in further signiﬁcant decreases in cell body
volume in HD mice in striatum (p¼0.0246) and primary motor
cortex layer V (p¼0.0413). There was no effect of iron supple-
mentation in wild-type mice. We estimated striatal neuronal
numbers using the optical fractionator stereological tool. While
there was a signiﬁcant decrease in neuronal numbers in HD mice
[33] there was no effect of iron supplementation on estimates in
wild-type or HD mice (not shown). Also, there was no effect of iron
treatment on whole brain weights in HD or wild-type mice (not
shown).
Mutant huntingtin protein aggregates are commonly found in
mouse and human HD [34]. To investigate the effect of neonatal
iron supplementation on huntingtin aggregates we used confocal
microscopy and stereology to quantify neuronal cell body ag-
gregates in striatum (Fig. 4A–C) and cortex (D–F). In striatum,
compared to R6/2 HD controls (Fig. 4A), iron-supplemented R6/2
HD mice (B) had signiﬁcantly fewer detectable neuronal hun-
tingtin aggregates (p¼0.0279). In motor cortex layer V, compared
to the R6/2 control group (Fig. 4D), there was decreased neuronal
Fig. 2. Neonatal iron supplementation elevates markers of oxidative and energetic dysfunction in R6/2 HD but not wild-type mice. (A and B) Brain oxidized glutathione
(GSSG) in neonatal iron supplemented mice. Supplementation increases striatal (A) and cortical (B) GSSG in HD, but not wild-type mice, at 12 weeks of age. GSSG levels are
not affected by mutant huntingtin expression in striatum or cortex of 12-week-old R6/2 HD compared to wild-type mice. Asterisks indicate levels of signiﬁcance: n o0.05,
nn o0.01, nnn o0.001, n¼10. (C and D) Brain lactate in neonatal iron supplemented mice. Iron supplementation increases striatal (C) and cortical (D) lactate in HD, but not
wild-type mice, at 12 weeks of age. Graph bars: open¼wild-type; hatched¼HD; white¼no supplementation; and gray¼ iron supplemented. Asterisks indicate levels of
signiﬁcance: n o0.05, nn o0.01, nnn o0.001, n¼10.
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difference did not reach statistical signiﬁcance.
Brain iron status is unchanged by neonatal iron supplementation
We next addressed whether the potentiation of HD by iron
supplementation (Figs. 1–4) associated with changes in brain iron
status. First, we measured bulk brain regional iron levels. Con-
sistent with previous ﬁndings, in striata (Fig. 5A) and frontal cor-
tex (B), 12-week old R6/2 HD mice had signiﬁcantly elevated iron
compared to wild-type littermates (p¼0.0012 and o0.0001).
However, there was no effect of iron supplementation in HD mice.
In wild-type mice only, iron supplementation did increase cortical
iron (p¼0.0093). Ferritin is an intra-cellular iron buffer and its iron
content can increase with iron loading. We used size-exclusion
chromatography combined with ICP-MS (SEC-ICP-MS) to quantify
the amount of iron associated with the ferritin protein fraction in
frontal cortex. We found that R6/2 HD mice had signiﬁcantly more
iron in the ferritin fraction as compared to wild-type mice (Fig. 5C)
(p¼0.0003); however, there was no effect of iron supplementa-
tion. To address the possibility that there may be transient ele-
vated brain iron early in life we measured striatal (Fig. 5D) andcortical (E) iron in 5-week-old mice following neonatal dosing.
There was no effect of iron supplementation on brain iron levels.
We also measured brain copper and manganese. Copper and
manganese concentrations were increased in HD mice compared
to wild-type mice; however, there was no effect of iron supple-
mentation on copper or manganese status (see Table 1). To further
investigate whether neonatal iron treatment affected brain iron
status in HD mice we quantiﬁed the levels of the iron-responsive
proteins amyloid precursor protein (APP) and transferrin receptor
(TfR). We have previously reported that levels of both APP and TfR
are decreased in R6/2 HD brain [10]. APP promotes iron export
from cells by stabilizing ferroportin [35,36]. We found decreased
APP in striatum (Fig. 5F) (p¼0.0288) and cortex (G) (p¼0.0149) in
HD mice compared to wild-type mice. The transferrin receptor
was not decreased in striatum of R6/2 HD mice (Fig. 5H) but was
deceased in cortex (I) (po0.0001). There was no evidence of any
effect of neonatal iron supplementation on APP or TfR in wild-type
or R6/2 HD mice (Fig. 5F–I).
Given the absence of evidence to support a direct effect of
neonatal iron supplementation on brain iron homeostasis we in-
vestigated how supplementation changes the peripheral environ-
ment. Speciﬁcally, we measured peripheral markers of iron and
A B
C D
Fig. 3. Neonatal iron supplementation results in neuronal cell body atrophy in striatum and motor cortex in R6/2 HD but not wild-type mice. (A–D) Neuronal cell body size in
neonatal iron supplemented mice. (A and B) R6/2 HD mice have signiﬁcantly smaller striatal neuronal cell body size as compared to wild-type mice at 13 weeks of age.
Neonatal iron supplementation decreases striatal neuronal cell body volume in R6/2 HD, but not wild-type mice, at 13 weeks of age. (C and D) R6/2 HD mice have
signiﬁcantly smaller neuronal cell body volume in primary motor cortex layer V as compared to wild-type mice at 13 weeks of age. Neonatal iron supplementation decreases
neuronal volume in primary motor cortex layer V in HD, but not wild-type, mice. Bar¼20 mm. (A and C) Representative images from 40 mm Thionin-stained sections. (B and
D) Quantiﬁcation of cell body size. Arrowheads demonstrate size differences among neurons. Graph bars: open¼wild-type; hatched¼HD; white¼no supplementation; and
gray¼ iron supplemented. Asterisks indicate levels of signiﬁcance: n o0.05, nn o0.01, nnn o0.001, CB¼cell body, n¼10.
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saturation are widely used clinical markers of iron status. Serum
iron was unaltered by HD (Fig. 6A). However, iron supplementa-
tion decreased serum iron at 5 weeks (p¼0.0003) in both HD and
wild-type mice. At 13 weeks of age there was no effect of iron
supplementation (Fig. 6A). Transferrin saturation was increased in
HD controls as compared to wild-type controls at 5 weeks of age
(p¼0.0386). Further, at this age neonatal iron treatment decreased
transferrin saturation in both wild-type and HD mice (Fig. 6B)
(p¼0.0037 and 0.0206, respectively). However, at 13-weeks
transferrin saturation was signiﬁcantly increased in iron supple-
mented compared to control HD mice (p¼0.0263). To understand
this effect further we determined liver iron as liver can act as an
iron store [16]. In 5-week old animals, iron supplementation in-
creased liver iron levels in both R6/2 HD (po0.0001) and wild-
type littermates (po0.0001). However, at 13 weeks of age, neo-
natal iron treatment signiﬁcantly increased liver iron levels in R6/2
(po0.0001), but not wild-type mice (Fig. 6C). Finally, we mea-
sured plasma total glutathione levels as a marker of redox state;
differences between groups were not evident (Fig. 6D).Adult iron treatment does not potentiate HD outcomes in R6/2 mice
We next investigated whether increased iron intake during
adult life can potentiate HD in R6/2 mice. We compared the effects
of two or three dietary iron levels in our experiments (Fig. 7).
There was no effect of iron intake level on rota-rod endurance
(Fig. 7A) or spontaneous wheel running activity (Fig. 7B) in HD
mice. However, there was an age-dependent decline in rota-rod
endurance in wild-type mice fed medium and high iron diets
(Fig. 7A). Dietary iron level did not alter striatal or cortical oxidized
glutathione levels in HD or wild-type 12-week-old mice (data not
shown). R6/2 HD mice had elevated striatal and cortical lactate
(p¼0.0002 and o0.0001, respectively); however, there was no
effect of iron intake on brain lactate (data not shown). R6/2 HD
mice had decreased striatal neuronal volume (p¼0.0254) but
there was no effect of dietary iron level on this outcome (Fig. 7C).
There was also no effect of iron treatment on neuronal mutant
huntingtin aggregates in HD mice (Fig. 7D). Bulk iron levels were
increased in striatum (Fig. 7E) and cortex (F) in HD mice
(po0.0001 and 0.0020, respectively); however, there was no
A B C
D E F
Fig. 4. Neonatal iron supplementation decreases mutant huntingtin aggregate load in R6/2 HD striata. Mutant aggregate load was quantiﬁed by confocal microscopy in
striatum (A–C) and primary motor cortex layer 6 (D–F) of R6/2 HD mice at 13 weeks of age. The percentage of HD striatal neuronal cell bodies (red) containing micro-
scopically visible aggregates (green) is signiﬁcantly decreased in neonatal iron supplemented (B) as compared to control (A) HD mice. There is decreased mutant huntingtin
aggregate load in motor cortex of neonatal iron supplemented (E) compared to control (D) HD mice, but this difference was not statistically signiﬁcant. Bar¼20 mm. Graph
bars: hatched¼HD; white¼no supplementation; and gray¼ iron supplemented. Asterisks: n o0.05, n¼10.
K.L. Berggren et al. / Redox Biology 4 (2015) 363–374 369effect of iron treatment on brain iron. Finally, we determined
transferrin saturation as a peripheral marker of iron status. In HD
mice, transferrin saturation was decreased with elevated dietary
iron intake (p¼0.0187) (Fig. 7G).Discussion
R6/2 HD mice express the exon-1 fragment of polyglutamine-
expanded human huntingtin protein (htt) [37]. They develop ad-
vanced disease by 12 weeks of age and demonstrate many features
found in human HD at the motor function, brain pathology and
molecular levels. Therefore, R6/2 HD mice represent a model of
rapidly developing HD that is valuable for studying disease mod-
ifying interventions. Here we show that neonatal iron supple-
mentation potentiates R6/2 mouse HD as measured by behavioral,
neuropathological and biochemical outcomes (Figs. 1–5). Effects of
iron supplementation were not present in early-adult life
(5 weeks) consistent with an absence of iron toxicity, but were
manifest with early-advanced HD at 12 weeks of age (Fig. 1). Im-
portantly, the effects of neonatal iron supplementation did not
occur in wild-type litter-mate mice consistent with an interaction
between the HD gene and iron intake. Iron supplementation had
no effect in adult R6/2 HD mice (Fig. 7). The ﬁndings indicate that
in this mouse model of HD the neonatal-life stage is a period of
speciﬁc vulnerability to the effects of elevated iron intake.
Perinatal iron deﬁciency is a world-wide nutritional problem
that can lead to delayed neurocognitive development [38]. During
the neonatal-infant period, iron absorption is inefﬁcient, brain
growth is rapid and brain iron uptake is high; while mechanisms
to maintain brain iron homeostasis are not fully developed (re-
viewed in [39]). Human milk replacer formulas typically containlevels of iron greater than that found in human milk, up to forty
times more iron is present in some replacers [20]. Despite elevated
iron intake from milk replacers, few studies have addressed the
effect of elevated neonatal iron intake on brain aging and inter-
actions with neurodegenerative diseases. In our neonatal mouse
iron supplementation study, we used a level of iron estimated to
provide forty times more iron than the mouse pup would have
received naturally from mouse milk as previously reported [20].
Body surface area is an alternative, and perhaps preferable, ap-
proach to translate dose across species [40]. Using this method the
dose we used in mice translates to less than a forty-fold increase in
iron intake in a human infant. Based on brain developmental
staging, dosing on days 10–17 is equivalent to an infant receiving
iron supplementation from birth through 20 weeks [41]. There-
fore, the dose and age of supplementation of iron we used in the
neonatal study is relevant to human nutrition. Using this regimen,
we found signiﬁcant deleterious effects of neonatal iron supple-
mentation in R6/2 mice that spanned behavioral (Fig. 1), bio-
chemical markers of oxidative stress and energetic dysfunction
(Fig. 2), and quantitative pathology (Fig. 3) domains. We ad-
ditionally found that iron supplemented HD mice had fewer
striatal aggregates (Fig. 4). While we did not measure soluble
mutant htt levels, fewer aggregates are compatible with po-
tentiated HD because neurons with fewer aggregates may have
increased soluble mutant htt which is more toxic than aggregated
mutant htt [42]. Taken together, the presence of effects of neonatal
iron supplementation on multiple outcomes in HD mice suggests
that similar effects of neonatal iron supplementation could occur
in human HD.
Exacerbations of oxidative stress are common features of
neurodegenerative diseases (reviewed in [43]). Glutathione (GSH)
is an electron donor required for several enzyme systems
Fig. 5. Neonatal iron supplementation does not alter markers of brain iron status in HD mice. (A and B) Brain iron levels at 12 weeks of age. Iron levels are signiﬁcantly
elevated in striatum (A) and cortex (B) of 12-week-old R6/2 HD as compared to wild-type control mice. n¼10–11. (B) Iron supplementation signiﬁcantly increases cortical
iron in wild-type control mice but not in R6/2 HD mice. (C) Iron levels associated with ferritin protein fraction in cortex at 12 weeks of age. Protein extracts from 12-week-old
cortex were resolved by size-exclusion chromatography (SEC) followed by in-line ICP-MS for iron content. Solid line¼mean; dotted line¼standard error. There is a sig-
niﬁcantly increased iron content of the ferritin protein fraction in R6/2 HD mice. There is no effect of iron supplementation on ferritin-associated iron. n¼5. (D and E) Brain
iron levels at 5 weeks of age. There is no effect of genotype or iron supplementation on striatal (D) or cortical (E) iron level. n¼10–11. (F–I) Levels of iron-responsive proteins
in HD mouse brain. (F and G) Amyloid precursor protein (APP) levels are signiﬁcantly decreased in striata (F) and cortices (G) of HD mice. There is no effect of neonatal iron
supplementation. (H and I) Transferrin receptor levels are decreased in cortex of HD mice compared to wild-type mice. There is no effect of neonatal iron supplementation in
striatum (H) or cortex (I). Graph bars: open¼wild-type; hatched¼HD; white ¼ no supplementation; and gray¼ iron supplemented. n¼7–8, asterisks indicate the level of
signiﬁcance: n o0.05, nn o0.01, nnn o0.001.
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cess, GSH is oxidized to GSSG (oxidized glutathione), an indicator
of oxidative stress. GSSG is increased in a cell line model of HD
[44] and also the brains of N171-82Q HD mice [23]. We found that
iron supplemented HD mice had signiﬁcant increases in cortical
and striatal GSSG. While HD mice had signiﬁcantly increased
cortical and striatal GSH compared to wild-type mice, this effect
was not exacerbated by iron supplementation. Brain lactate is
elevated in human HD and is one valuable marker for energetic
dysfunction [45]. We have previously found elevated brain lactate
in R6/2 HD mice [26]; the current ﬁndings show that iron sup-
plementation increases brain lactate levels in HD but not wild-
type mice. Taken together, these ﬁndings indicate a state of me-
tabolic dysregulation in R6/2 HD mice.
Iron homeostasis requires the regulation of intestinal ironabsorption, storage as ferritin, transport in blood and uptake by
brain and other organs [16]. We have previously shown altered
expression levels of the iron homeostatic proteins, transferrin re-
ceptor and amyloid precursor protein, in R6/2 HD brain [10,26].
Amyloid precursor protein promotes iron export from cells by
stabilizing surface ferroportin [35,36]; decreased levels in R6/2 HD
mice may explain elevated brain iron [10]. While brain and body
iron homeostasis is tightly regulated, it is still modiﬁable by
dietary iron intake. For example, early-life iron overload in mice
has been shown to have signiﬁcant effects on neurobehavioral
performance [18,19]. Furthermore, neonatal iron supplementation
in wild-type mice has been shown to alter brain iron levels in
adult animals [18,20,46]. Consistent with these ﬁndings, we found
increased cortical iron in 12-week-old wild-type mice that were
supplemented as neonates (Fig. 5B). We were surprised however
K.L. Berggren et al. / Redox Biology 4 (2015) 363–374 371that there was no increase in striatal or cortical iron in neonatally-
supplemented HD mice (Fig. 5A and B). Furthermore, we found no
evidence of changes in cortical iron status in HD mice using SEC-
ICP-MS to quantify iron levels in the ferritin protein fraction
(Fig. 5C). We additionally undertook Western blot analysis of the
iron-responsive amyloid precursor protein and the transferrin re-
ceptor as an alternative approach to detect changes in brain iron
homeostasis but did not detect effects of iron supplementation
(Fig. 5F–I). Brain iron homeostasis is complex and we cannot rule
out the possibility of undetected changes in brain iron includingTable 1
Brain metal concentrations.
Striatum
WT-saline WT-iron HD-saline HD-iron
Copper 2.11 (0.12) 1.94 (0.12) 2.43 (0.12) 2.43 (0.12
Manganese 0.14 (0.01) 0.13 (0.01) 0.16 (0.01)ƗƗ 0.15 (0.01
Values represent concentrations in mg/g wet weight (standard error); WT¼wild-type, H
n po0.01 vs. WT-iron.
nn po0.01 vs. WT-saline.
nnn po0.001 vs. WT-saline.
# po0.05 vs. WT-iron.
## po0.05 vs. WT-iron.
### po0.0001 vs. WT-iron.
Fig. 6. Neonatal iron supplementation alters peripheral markers of iron status. (A and
mice at 5 and 13 weeks of age. n¼9–10. (A) Serum iron levels are decreased by iron
a¼0.0571). There is no difference in serum iron in 12-week-old mice. (B) Serum transfer
5 weeks. Iron supplementation decreases transferrin saturation in 5-week wild-type a
transferrin saturation at 13 weeks. (C) Liver iron levels. Iron supplemented HD and wild
iron is elevated in HD mice only. n¼10–11. (D) There is no effect of genotype or iron s
hatched¼HD; white¼no supplementation; and gray¼ iron supplemented. n¼10, asterialtered distribution within cell compartments. We investigated
peripheral iron and redox status as an alternative path to mod-
iﬁcation of HD (Fig. 6). Findings reveal that R6/2 HD mice, com-
pared to wild-types, have unaltered serum iron but that there is an
early and transient decrease in serum iron at 5 weeks in iron
supplemented mice, that is absent at 13 weeks (Fig. 6A). This ap-
pears to be explained by the increase in iron sequestration by liver
at this age (Fig. 6C). Transferrin saturation was decreased at
5 weeks by iron supplementation; however, at 13-weeks iron-
supplemented HD mice had elevated transferrin saturationCortex
WT-saline WT-iron HD-saline HD-iron
)n 3.49 (0.12) 3.53 (0.12) 3.96 (0.12)nn 3.96 (0.12)Ɨ
) 0.33 (0.01) 0.32 (0.01) 0.39 (0.01)nnn 0.41 (0.01)ƗƗƗ
D¼R6/2.
B) Serum iron status markers in iron-supplemented and control wild-type and HD
supplementation in wild-type and HD mice at 5 weeks (main effect p¼0.0003;
rin saturation is increased in HD mice compared to wild-type litter-mate controls at
nd HD mice. R6/2 HD mice supplemented with iron as neonates have increased
-type litter-mate mice have elevated liver iron at 5 weeks of age; at 13 weeks liver
upplementation on plasma total glutathione (GSH). Graph bars: open¼wild-type;
sks indicate the level of signiﬁcance: n o0.05, nn o0.01, nnn o0.001.
Fig. 7. Increased iron intake in adult R6/2 mice does not potentiate HD. (A–C) Motor performance testing in wild-type and R6/2 HD mice fed different levels of iron from
5 weeks of age. (A) HD mice perform signiﬁcantly worse than wild-type litter-mate mice on a rota-rod motor endurance test. At each age graph bars, from left to right,
represent iron levels in parts-per-million (ppm): wild-type (WT) 50 (white-hatched), WT 150 (gray-hatched), WT 500 (black), HD 50 (white-hatched), HD 150 (gray-
hatched) and HD 500 (black). There is no effect of iron intake level in HD mice. Wild-type mice fed 150 and 500 ppm iron demonstrate age-dependent decline in rota-rod
activity. n¼13–15. (B) HD mice perform worse on a spontaneous wheel running test in the dark periods. There is no effect of iron intake level. At each age graph bars, from
left to right, represent: WT 50 (white-hatched), WT 500 (black), HD 50 (white-hatched) and HD 500 (gray). n¼9–10. (C) Striatal neuronal cell body volume is decreased in
R6/2HD mice at 12 weeks of age, compared to wild-type litter mates. There is no effect of iron intake level. n¼8–10. (D) There is no effect of iron intake level on mutant
huntingtin aggregates in HD mice, n¼7–10. (E and F) Iron concentrations in striatum (E) and frontal cortex (F) at are increased at 12 weeks of age; there is no effect of iron
treatment. n¼10–11. (G) Low iron intake results in increased transferrin saturation at 12 weeks of age in HD but not wild-type mice. n¼10–12. Graph bars: open¼wild-type
and hatched¼HD; dietary iron levels, white¼50 ppm, light gray¼150 ppm and dark gray¼500 ppm. Asterisks indicate the level of signiﬁcance: n o0.05, nn o0.01,
nnn o0.001.
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but increased iron-loading of remaining transferrin suggesting
dysregulation of peripheral iron regulation in HD. Overall, both
wild-type and HD mice show similar short and longer term per-
ipheral responses to iron supplementation. However, differences
in these responses in HD mice show that mutant htt affects the
systemic response to iron intake level; this different response may
be involved in the mechanism of how neonatal iron supple-
mentation potentiates HD and indicates a complex interplay be-
tween iron intake, huntingtin and systemic iron metabolism.
Multivitamin–multimineral (MVMM) supplements are used by
about a third of the US population [47]. The recommended daily
allowance of iron for all adult men and women over 50 is 8 mg
[48]. Many generic MVMM tablets contain 18 mg iron, a level only
recommended for women 19–50 years of age. There is therefore
potential for over-supplementation in part of the population.
Based on this, we investigated the effect of elevated iron intake in
adult R6/2 HD mice. Even though there was a ten-fold difference
between low and high dietary iron intake levels (see Materials and
Methods section) we found no effect of iron intake level in R6/2
HD mice (Fig. 7). Wild-type mice fed the medium and high iron
diets demonstrated some decline in rota-rod endurance (Fig. 7A);
however, there was no other evidence for an effect of iron intake in
wild-type mice. Unlike the neonatal iron supplementation study
(Fig. 6B), adult iron supplementation did not elevate cortical iron
levels in wild-type mice (Fig. 7E). However, there was a differential
response of blood transferrin saturation between wild-type and
HD mice (Fig. 7G) which is consistent with altered systemic re-
sponses to iron-loading in the neonatal study. Together these data
suggest that dysregulation of peripheral iron homeostasis also
occurs in adult HD mice.Conclusions
Iron supplementation in neonatal HD mice potentiates the
course of HD in R6/2 mice. Increased levels of brain oxidized
glutathione and lactate were found in iron supplemented mice
consistent with a role of oxidative stress and energetic dysfunction
in disease potentiation. HD potentiation occurred in the absence of
detectable changes in brain iron status demonstrating that iron’s
role in HD cannot be simply deﬁned at the level of increased brain
regional concentrations. The ﬁndings support a role of iron nu-
trition during early brain development as a modiﬁer of HD. This
period of developmental vulnerability to elevated iron intake
could also be present in HD gene-positive infants. Prospective
clinical investigation of this phenomenon in humans is challen-
ging due to the usual adult age of HD clinical onset; however,
retrospective or biomarker studies could allow further investiga-
tion of the relationship between neonatal iron intake and HD
onset or progression.Acknowledgments
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